Berdy & Malhotra, PC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$4,535	1
2022	Research	$37,010	6
2021	Research	$8,301	2
2020	Research	$64,812	10

Breakdown

Who paid Research payments · program years 2020–2023

Sun Pharmaceutical Industries Inc. $114,657 19 payments

Studies the money was for Research payments · program years 2020–2023

A Phase 3, Multicenter, Randomized, Double-Masked, Parallel-Group, Comparative Study to Evaluate the Clinical Efficacy and Safety of ISV-305 (0.1% Dexamethasone) Compared to Vehicle in the Treatment of Subjects With Blepharitis $61,609 7 payments
Effect of Cequa in Subjects With Dry Eye Disease $49,845 9 payments
A Phase 3, Randomized, Multicenter, Double-masked Study to Compare the Ocular Safety, Tolerability, and Efficacy of ISV-305 (0.1% Dexamethasone in DuraSite 2) to DuraSite 2 Vehicle for the Treatment of Inflammation and Pain Associated With Cataract Surgery $3,204 3 payments

What the money was spent on Research payments · program years 2020–2023

Other $64,812 10 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.